sc cardiologia clinica riabilitativa sarzana 1/33 db 7/5/2011 terza sessione l’anziano...
TRANSCRIPT
SC Cardiologia Clinica RiabilitativaSarzana
1/33db 7/5/2011
TERZA SESSIONEL’ANZIANO CARDIOPATICO CON
CO-MORBILITÀ
Infarto miocardico e Broncopneumopatia
Ostruttiva
Daniele Bertoli
SC Cardiologia Clinica RiabilitativaSarzana
2/33db 7/5/2011
COPD
• The 4th leading cause of death in the USA (behind heart desease, cancer, cerebrovascular disease)
• In 1990, COPD was ranked 12th as a burden of disease; by 2020 it is projected to rank 5°
• The majority of patients with COPD die from cardiovascular disorders or cancer, not respiratory disease
SC Cardiologia Clinica RiabilitativaSarzana
3/33db 7/5/2011
SC Cardiologia Clinica RiabilitativaSarzana
4/33db 7/5/2011
COPD: Definition
• lung disease characterized by chronic obstruction of lung airflow that interferes with normal breathing and is not fully reversible.
• The airflow limitation is usually both progressive and associated with an abnormal inflammatory response of the lungs.
• The more familiar terms 'chronic bronchitis' and 'emphysema' are no longer used, but are now included within the COPD diagnosis.
• COPD is not simply a "smoker's cough" but an under-diagnosed, life-threatening lung disease.
SC Cardiologia Clinica RiabilitativaSarzana
5/33db 7/5/2011
COPD: Definition• diagnosis is confirmed by spirometry• COPD should be considered in any patient
who has symptoms of cough, sputum production, or dyspnea and/or a history of exposure to risk factors for the disease
• Chronic cough and sputum production often precede the development of airflow limitation by many years, although not all individuals with cough and sputum production go on to develop COPD
SC Cardiologia Clinica RiabilitativaSarzana
6/33db 7/5/2011
PARAMETRI SPIROMETRICI
• FEV1 o VEMS (Volume espiratorio forzato in 1 secondo) = quantità di aria emessa nel primo secondo di espirazione forzata
• FVC (Capacità Vitale Forzata) = quantità massima di aria (misurata in litri) che può essere espulsa in un’espirazione forzata dopo un’ispirazione completa.
• FEV1/FVC = Un valore inferiore al 70% indica un deficit ostruttivo e alta probabilità di BPCO.
SC Cardiologia Clinica RiabilitativaSarzana
7/33db 7/5/2011
Spirometria Normale e TracciatoSpirometrico di Pazienti con BPCO
SC Cardiologia Clinica RiabilitativaSarzana
8/33db 7/5/2011
Classificazione spirometrica di gravitàdella BPCO basata sul VEMS
post-broncodilatatore
SC Cardiologia Clinica RiabilitativaSarzana
9/33db 7/5/2011
Heart disease and COPD
• The most common cardiac abnormalities in patients with COPD are cor pulmonale and pulmonary hypertension
• The prevalence of atrial fibrillation, atherosclerosis, and CHF is also high among patients with COPD
SC Cardiologia Clinica RiabilitativaSarzana
10/33db 7/5/2011
Atherosclerosis and COPD
• Although some of the association between COPD and atherosclerosis may be the result of common risk factors such as tobacco use, epidemiological evidence suggests that impaired lung function is a risk factor for increased cardiovascular death independent of tobacco use
SC Cardiologia Clinica RiabilitativaSarzana
11/33db 7/5/2011
The Relationship Between Reduced Lung Function and Cardiovascular Mortality - A Population-Based Study and a Systematic Review of the LiteratureChest 2005;127;1952-1959
SC Cardiologia Clinica RiabilitativaSarzana
12/33db 7/5/2011
The Relationship Between Reduced Lung Function and Cardiovascular Mortality - A Population-Based Study and a Systematic Review of the LiteratureChest 2005;127;1952-1959
SC Cardiologia Clinica RiabilitativaSarzana
13/33db 7/5/2011
Metaanalysis of studies that reported RR of cardiovascular mortality based on FEV1 quintiles.
Chest 2005;127;1952-1959
SC Cardiologia Clinica RiabilitativaSarzana
14/33db 7/5/2011
Metaanalysis of studies that reported RR of cardiovascular mortality among nonsmokers
Chest 2005;127;1952-1959
SC Cardiologia Clinica RiabilitativaSarzana
15/33db 7/5/2011
Relationship between FEV 1, smoking status, and OR for cardiovascular mortality for current smoker (dark grey squares), ex-smoker (white
squares), and never smoker (light grey squares)
Young RP , Hopkins R , Eaton TE . Forced expiratory volume in one second: not just a lung function test but a marker of premature death from all causes . Eur Respir J . 2007; 30(4): 616- 622
SC Cardiologia Clinica RiabilitativaSarzana
16/33db 7/5/2011Circulation 2003;107:1514-1519
SC Cardiologia Clinica RiabilitativaSarzana
17/33db 7/5/2011Circulation 2003;107:1514-1519
SC Cardiologia Clinica RiabilitativaSarzana
18/33db 7/5/2011
Association between chronic obstructive pulmonary diseaseand systemic inflammation: a systematic review and a metaanalysis Thorax 2004;59:574–580
Relationship between C-reactive protein (CRP) and COPD
SC Cardiologia Clinica RiabilitativaSarzana
19/33db 7/5/2011
Association between chronic obstructive pulmonary diseaseand systemic inflammation: a systematic review and a metaanalysis Thorax 2004;59:574–580
Relationship between fibrinogen and COPD
SC Cardiologia Clinica RiabilitativaSarzana
20/33db 7/5/2011
Association between chronic obstructive pulmonary diseaseand systemic inflammation: a systematic review and a metaanalysis Thorax 2004;59:574–580
Relationship between leucocytes and COPD
SC Cardiologia Clinica RiabilitativaSarzana
21/33db 7/5/2011
C-reactive Protein As a Predictor of Prognosis in ChronicObstructive Pulmonary Disease
Am J Respir Crit Care Med 175. 250–255, 2007
SC Cardiologia Clinica RiabilitativaSarzana
22/33db 7/5/2011
COPD could be considered as part of a “chronic systemic inflammatory syndrome.”• cardiovascular diseases
• lung cancer
• peripheral skeletal muscle dysfunction
• nutritional abnormalities
• osteoporosis
• increased prevalence of diabetes
• chronic kidney diseaseCHEST 2011; 139(1):165–173
SC Cardiologia Clinica RiabilitativaSarzana
23/33db 7/5/2011
Cardiovascular Safety of Tiotropium in Patients With COPD
Chest 2010;137;20-30
SC Cardiologia Clinica RiabilitativaSarzana
24/33db 7/5/2011
Cardiovascular Safety of Tiotropium in Patients With COPD
Chest 2010;137;20-30
SC Cardiologia Clinica RiabilitativaSarzana
25/33db 7/5/2011
J. Am. Coll. Cardiol. 2006;47;2554-2560;
SC Cardiologia Clinica RiabilitativaSarzana
26/33db 7/5/2011
Long-term mortality according to COPD and statin use in patients with peripheral arterial disease
van Gestel YR , Hoeks SE , Sin DD , et al . Effect of statin therapy on mortality in patients with peripheral arterial disease and comparison of those with versus without associated chronic obstructive pulmonary disease . Am J Cardiol . 2008 ; 102 ( 2 ): 192 - 196
SC Cardiologia Clinica RiabilitativaSarzana
27/33db 7/5/2011
SC Cardiologia Clinica RiabilitativaSarzana
28/33db 7/5/2011
Beta-Blockers• Patients with COPD are at increased risk of CAD, and ß-
blockers play a pivotal role in the management of cardiovascular diseases.
• There is a general reluctance to use these substances in patients with COPD because of an unfounded fear of inducing bronchospasm.
• A large Cochrane review revealed that cardioselective beta-blockers did not adversely affect the FEV1 or induce respiratory symptoms compared with placebo, independent of the severity of the COPD.
• Given the demonstrated efficacy of b -blockers in treating CAD and CHF, the benefit of these medicaments outweighs the side effects and they should not be withheld from patients with COPD
SC Cardiologia Clinica RiabilitativaSarzana
29/33db 7/5/2011
Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis
of the Valsartan in Acute Myocardial Infarction Trial (VALIANT)
European Journal of Heart Failure (2009) 11, 292–298
SC Cardiologia Clinica RiabilitativaSarzana
30/33db 7/5/2011Arch Intern Med. 2010;170(10):880-887
SC Cardiologia Clinica RiabilitativaSarzana
31/33db 7/5/2011Arch Intern Med. 2010;170(10):880-887
SC Cardiologia Clinica RiabilitativaSarzana
32/33db 7/5/2011Arch Intern Med. 2010;170(10):880-887
SC Cardiologia Clinica RiabilitativaSarzana
33/33db 7/5/2011
Take Home Messages
• La BPCO è un fattore di rischio cardiovascolare
• E’ probabile che meccanismi fisiopatologici simili, di tipo infiammatorio, siano presenti nella BPCO e nella malattia aterosclerotica
• Le terapie pneumologiche più efficaci (tiotropio in particolare) sono efficaci anche per ridurre il rischio CV dei pazienti con BPCO
• Le terapie cardiologiche più efficaci (statine, beta-bloccanti, inibitori RAAS) sono efficaci anche nella BPCO
SC Cardiologia Clinica RiabilitativaSarzana
34/33db 7/5/2011
OSPEDALE SAN BARTOLOMEO DI SARZANA